Cardiometabolic disease burden and steroid excretion in benign adrenal tumors

Prete, Alessandro; Subramanian, Anuradhaa; Bancos, Irina; Chortis, Vasileios; Tsagarakis, Stylianos; Lang, Katharina; Macech, Magdalena; Delivanis, Danae; Pupovac, Ivana; Reimondo, Giuseppe; Marina, Ljiljana; Deutschbein, Timo; Balomenaki, Maria ; O'reilly, Michael; Gilligan, Lorna; Jenkinson, Carl; Bednarczuk, Tomasz ; Zhang, Catherine; Dusek, Tina; Diamantopoulos, Aristidis

Document Version
Peer reviewed version

Link to publication on Research at Birmingham portal

Cardiometabolic disease burden and steroid excretion in benign adrenal tumors: a cross-sectional multi-center study

Running title: Cardiometabolic disease burden in benign adrenal tumors

Alessandro Prete[1,2,3], Anuradhaa Subramanian[4], Irina Bancos[1,5], Vasileios Chortis[1,2,3], Stylianos Tsagarakis[6], Katharina Lang[1,2,3], Magdalena Macech[7], Danae A. Delivanis[5], Ivana D. Pupovac[8], Giuseppe Reimondo[9], Ljiljana V. Marina[10], Timo Deutschbein[11,12], Maria Balomenaki[6], Michael W. O'Reilly[1,13], Lorna C. Gilligan[1], Carl Jenkinson[1], Tomasz Bednarczuk[7], Catherine D. Zhang[5], Tina Dusek[8], Aristidis Diamantopoulos[6], Miriam Asia[2,3], Agnieszka Kondracka[7], Dingfeng Li[5], Jimmy R. Masjkur[14], Marcus Quinkler[15], Grethe Å. Ueland[16], M. Conall Dennedy[17], Felix Beuschlein[18,19], Antoine Tabarin[20], Martin Fassnacht[11], Miomira Ivovic[10], Massimo Terzolo[9], Darko Kastelan[8], William F. Young Jr[5], Konstantinos N. Manolopoulos[1], Urszula Ambroziak[7], Dimitra A. Vassiliadi[6], Angela E. Taylor[1], Alice J. Sitch[4,21], Krishnarajah Nirantharakumar[1,2,4], and Wiebke Arlt[1,2,3,21] for the ENSAT EURINE-ACT Investigators

[1]Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK. [2]Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK. [3]Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. [4]Institute of Applied Health Research, University of Birmingham, Birmingham, UK. [5]Division of Endocrinology, Metabolism, Diabetes and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. [6]Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece. [7]Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland. [8]Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia. [9]Division of Internal Medicine, University of Turin, San Luigi Hospital, Turin, Italy. [10]Department for Obesity, Reproductive and Metabolic Disorders, Clinic for Endocrinology, Diabetes and Metabolic

25 Diseases, University Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade,

26 Belgrade, Serbia. [11]Department of Internal Medicine I, Division of Endocrinology and Diabetes,

27 University Hospital, University of Würzburg, Würzburg, Germany. [12]Medicover Oldenburg MVZ,

28 Oldenburg, Germany. [13]Department of Medicine, Royal College of Surgeons in Ireland, University

29 of Medicine and Health Sciences, Dublin, Republic of Ireland. [14]Department of Medicine III and

30 Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden,

31 Dresden, Germany. [15]Endocrinology in Charlottenburg, Berlin, Germany. [16]Department of

32 Endocrinology, Haukeland University Hospital, Bergen, Norway. [17]Department of Endocrinology,

33 University Hospital Galway, Newcastle, Galway, Ireland. [18]Klinik für Endokrinologie,

34 Diabetologie und Klinische Ernährung, Universitäts-Spital Zürich (USZ) und Universität Zürich

35 (UZH), Zurich, Switzerland. [19]Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-

36 Universität München, Munich, Germany. [20]Service d'Endocrinologie, Centre Hospitalier

37 Universitaire, Hopital du Haut Leveque, Pessac, France. [21]NIHR Birmingham Biomedical

38 Research Centre, University of Birmingham and University Hospitals Birmingham NHS

39 Foundation Trust, Birmingham, UK.

40 **Corresponding author:**

41 Professor Wiebke Arlt

42 Institute of Metabolism and Systems Research

43 College of Medical and Dental Sciences

44 University of Birmingham

45 Birmingham, B15 2TT, United Kingdom

46 Email w.arlt@bham.ac.uk

47 **Word count:** 3348

48   **ABSTRACT**

49   **BACKGROUND:** Benign adrenal tumors are commonly discovered on cross-sectional imaging.

50   Mild autonomous cortisol secretion (MACS) is regularly diagnosed but its impact on

51   cardiometabolic disease in affected individuals is ill-defined.

52   **OBJECTIVE:** To determine cardiometabolic disease burden and steroid excretion in persons with

53   benign adrenal tumors with and without MACS.

54   **DESIGN:** Cross-sectional study.

55   **SETTING:** 14 endocrine secondary/tertiary care centers (recruitment 2011-2016).

56   **PARTICIPANTS:** 1305 prospectively recruited persons with benign adrenal tumors.

57   **MEASUREMENTS:** Cortisol excess was defined by clinical assessment and the 1mg-overnight

58   dexamethasone suppression test (serum cortisol <50 nmol/L: non-functioning adrenal tumor

59   [NFAT]; 50-138 nmol/L: possible MACS [MACS-1]; >138 nmol/L and absence of typical clinical

60   Cushing's syndrome [CS] features: definitive MACS [MACS-2]). Net steroid production was

61   assessed by multi-steroid profiling of 24-hour urine by tandem mass spectrometry.

62   **RESULTS:** Of the 1305 participants, 49.7% had NFAT (n=649; 64.1% women), 34.6% MACS-

63   1 (n=451; 67.2% women), 10.7% MACS-2 (n=140; 73.6% women), and 5.0% CS (n=65; 86.2%

64   women). Prevalence and severity of hypertension were higher in MACS-2 and CS than NFAT

65   (adjusted prevalence ratios (aPRs) for hypertension: MACS-2 1.15 [95%CI 1.04-1.27], CS 1.37

66   [95%CI 1.16-1.62]; aPR for use of ≥3 anti-hypertensives: MACS-2 1.31 [95%CI 1.02-1.68], CS

67   2.22 [95%CI 1.62-3.05]). Type 2 diabetes was more prevalent in CS than NFAT (aPR 1.62 [95%CI

68   1.08-2.42]), and more likely to require insulin therapy in MACS-2 (aPR 1.89 [95%CI 1.01-3.52])

69   and CS (aPR 3.06 [95%CI 1.60-5.85]). Urinary multi-steroid profiling revealed an increase in

70   glucocorticoid excretion from NFAT over MACS-1 and MACS-2 to CS whilst androgen excretion

71   decreased.

72   **LIMITATIONS:** Cross-sectional design, selection bias possible.

73   **CONCLUSION:** MACS is a cardiometabolic risk condition that predominantly affects women

74   and warrants regular assessment for hypertension and type 2 diabetes.

INTRODUCTION

Adrenal masses are discovered in approximately 5% of cross-sectional imaging studies (1, 2). Benign adrenal tumors are the most common underlying entity; in the largest prospective study to date, ENSAT EURINE-ACT (3), they represented 1513 (89.7%) of 1686 incidentally discovered adrenal masses. Benign adrenal masses can be non-functioning adrenal tumors (NFAT) or autonomously overproduce steroids, most frequently cortisol. Clinically overt cortisol excess, Cushing's syndrome (CS), usually presents with typical clinical signs including proximal myopathy and purple striae (4). CS is rare but potentially life-threatening due to the metabolically adverse consequences of cortisol excess, including type 2 diabetes, hypertension, and dyslipidemia, the main drivers of increased cardiovascular mortality in the affected persons (4, 5). Mild autonomous cortisol secretion (MACS), previously also termed subclinical CS, is regularly diagnosed in persons with benign adrenal tumors. MACS is defined by failure to suppress serum cortisol sufficiently after overnight administration of 1mg dexamethasone (6), but in the absence of the typical clinical signs of cortisol excess. Previous case series identified MACS in up to 35% of persons with benign adrenal tumors, making it the most common hormonal abnormality observed in this population (6, 7). However, while CS is a well-established cause of increased cardiometabolic morbidity and mortality, the evidence regarding the impact of MACS on cardiometabolic disease risk is scarce and heterogeneous. In a recent systematic review and meta-analysis of studies reporting on the prevalence of cardiometabolic comorbid conditions in persons with NFAT and MACS (8), hypertension was the most common occurrence (64.0% in MACS vs. 58.2% in NFAT). Persons with MACS were more likely to present with prediabetes (50.0% vs. 14.4%) and type 2 diabetes (28.1% vs. 14.4%), while the prevalence of dyslipidemia was at a similar level in MACS and NFAT (approximately 34%). However, evidence regarding the

103 cardiometabolic risk of persons with MACS is almost exclusively derived from observational

104 studies of small sample size, thereby limiting the interpretation of the results.

105 Here we report a cross-sectional study investigating the clinical characteristics, cardiometabolic

106 burden, and urinary steroid excretion in 1305 prospectively recruited persons with benign adrenal

107 tumors and different degrees of cortisol excess.

108 **METHODS**

109 **Subject selection**

110 Persons with benign adrenal tumors were drawn from the ENSAT EURINE-ACT study (3), which

111 had prospectively recruited adults (≥18 years) with newly diagnosed adrenal tumors >1cm from

112 2011 to 2016 through 14 secondary and tertiary care centers with expertise in the management of

113 adrenal tumors in 11 countries, participating in the European Network for the Study of Adrenal

114 Tumors (ENSAT; www.ensat.org). We included all EURINE-ACT participants who were

115 diagnosed with benign adrenocortical adenomas and had undergone standardized endocrine

116 assessment for exclusion of cortisol excess (9, 10), with measurement of endocrine parameters

117 carried out in the recruitment center. We excluded participants with confirmed primary

118 aldosteronism diagnosed according to current guidelines (11) and participants with cortisol excess

119 due to bilateral macronodular adrenal hyperplasia. We included 1305 (82%) of 1588 otherwise

120 eligible persons with benign adrenal tumors, as 283 had no available results for the 1-mg overnight

121 dexamethasone suppression test (1mg-DST) that is required for the diagnosis of MACS (**Fig. 1**).

122 In accordance with recent guidelines (6), we defined the presence of MACS as failure to suppress

123 morning serum cortisol concentration to <50 nmol/L after administration of 1mg dexamethasone

124 orally at 11 pm the preceding night (1mg-DST) in the absence of clinical features indicative of CS

125   (e.g. proximal myopathy, moon face, dorsocervical and supraclavicular fat pads, purple striae).

126   Persons with MACS were further subdivided into MACS-1 (possible autonomous cortisol

127   secretion; serum cortisol in the 1mg-DST 50-138 nmol/L) and MACS-2 (definitive autonomous

128   cortisol secretion; serum cortisol in the 1mg-DST >138 nmol/L) (6). Persons with current or recent

129   (<6 months) intake of drugs known to alter steroid synthesis or metabolism were excluded. All

130   centers had ethical approval for pseudonymized phenotype recording in the online ENSAT

131   database and all participants of the EURINE-ACT study provided written informed consent.

132   We used the information available at the time of adrenal tumor diagnosis (baseline assessment).

133   Variables obtained through the online ENSAT database included demographic data (sex, age, body

134   mass index, BMI), tumor characteristics (maximum diameter and location), information about

135   cardiometabolic morbidity (hypertension, dysglycemia, dyslipidemia), and endocrine test results

136   (adrenocorticotropic hormone, ACTH; serum dehydroepiandrosterone sulfate, DHEAS; 24-hour

137   urinary free cortisol, UFC). We then asked each site to review the available information against

138   their local databases to obtain any variables that were missing in the online ENSAT database (for

139   details see **Appendix Table 1**).

140   **Definitions of cardiometabolic outcomes**

141   We calculated the prevalence of hypertension, prediabetes, type 2 diabetes, and dyslipidemia

142   considering the clinical information available at the time of adrenal tumor diagnosis. We also

143   identified subjects with a more severe clinical phenotype, specifically those with hypertension

144   treated with ≥3 anti-hypertensives and those requiring insulin to manage their type 2 diabetes (for

145   details see **Appendix Table 1**).

146   *Hypertension:* Participants were considered as having hypertension if they had a doctor diagnosis

147   or if they were prescribed medications for hypertension.

148 *Treatment with ≥3 anti-hypertensives:* Participants with hypertension were chosen for a subgroup

149 analysis to study prescription of ≥3 antihypertensives as an outcome, in line with established

150 American Heart Association criteria (12).

151 *Glucose metabolism status:* Participants were considered as having type 2 diabetes if they had a

152 doctor diagnosis or if they were prescribed antidiabetic medications. Prediabetes and type 2

153 diabetes were also diagnosed based on glycated hemoglobin results according to American

154 Diabetes Association criteria (13).

155 *Type 2 diabetes requiring insulin:* Participants with type 2 diabetes were chosen for a subgroup

156 analysis to study insulin therapy as an outcome.

157 *Dyslipidemia:* The prescription of lipid-lowering agents was considered as a proxy for

158 dyslipidemia. We only considered subjects taking lipid-lowering agents other than for secondary

159 cardiovascular prevention, after excluding those with a history of stroke, cerebral hemorrhage,

160 cerebral thrombosis, ischemic heart disease, or angina, in line with American College of

161 Cardiology/American Heart Association criteria (14).

162 **Urine multi-steroid profiling**

163 Each study participant provided a 24-hour urine sample that was sent for centralized measurement

164 at the Steroid Metabolome Analysis Core, Institute of Metabolism and Systems Research,

165 Birmingham, UK. Multi-steroid profiling was carried out by liquid chromatography-tandem mass

166 spectrometry (LC-MS/MS) with quantification of the 24-hour urinary excretion of 16 distinct

167 steroid metabolites (**Appendix Table 2** and **Appendix Fig.1**), as previously described (3). Multi-

168 steroid profiling results in persons with MACS-1, MACS-2, and CS were compared to those with

169 NFAT.

170 **Statistical analysis**

8

171 Poisson regression with robust variance (15) was fitted to obtain crude and adjusted prevalence

172 ratios (PR) of hypertension, prediabetes, type 2 diabetes, and dyslipidemia in persons with MACS-

173 1, MACS-2, and CS using NFAT as the reference group. The models were adjusted for age, sex,

174 and BMI. In order to provide prevalence ratios using Poisson models, the categorical glucose

175 metabolism outcome variable was replaced with two separate binary outcomes: (a) dysglycemia

176 (combination of pre-diabetes and type 2 diabetes – subjects with NFAT and normal glucose

177 metabolism were used as the reference) and (b) type 2 diabetes (the combined group of subjects

178 with NFAT and with either pre-diabetes or normal glucose metabolism was used as the reference).

179 In sub-groups of subjects with hypertension and type 2 diabetes, Poisson regression models were

180 fitted to estimate the crude and adjusted PRs of treatment with ≥3 anti-hypertensives and insulin

181 use, respectively. Missing data for the clinical outcomes were replaced using multiple imputation

182 using chained equations through logistic models with the following covariates: age, sex, and BMI

183 category. Resistant hypertension, type 2 diabetes and insulin treatment were imputed within a

184 conditional sample of subjects with hypertension, dyslipidemia, and type 2 diabetes, respectively.

185 Outside these conditional samples, missing values for these variables were replaced with the

186 conditional constant (0/absent).

187 Associations between continuous outcomes, including 24-hour urine steroid excretion, were

188 determined by linear regression after log-transformation of all outcomes to reduce skewness in the

189 dataset. Associations between the log-transformed outcome and the variable of interest were

190 reported as sympercents (16) and all models were adjusted for age, sex, and BMI. Statistical

191 analyses were carried out using Stata Statistical Software: Release 16 (College Station, TX:

192 StataCorp LLC) and GraphPad Prism 9 (San Diego, CA: GraphPad Software Inc.).

193 **Role of the funding source**

194 The funders of the study had no role in study design, data collection, data analysis, data

195 interpretation, or writing of the report. The corresponding author had access to all the data and had

196 final responsibility for the decision to submit for publication.

197 **RESULTS**

198 **Clinical and endocrine characteristics**

199 Between 2011 and 2016, 1305 persons with newly diagnosed non-aldosterone producing

200 adenomas underwent a 1mg-DST and were prospectively assessed for clinical signs of cortisol

201 excess (**Fig. 1**, **Appendix Table 3**). Less than half of them achieved normal suppression of serum

202 cortisol after the 1mg-DST (NFAT n=649, 49.7%). The vast majority of those with abnormal

203 results lacked the distinctive clinical features of overt cortisol excess (MACS-1, n=451 [34.6%];

204 MACS-2, n=140 [10.7%]), while 65 (5.0%) were diagnosed with clinically overt CS including 37

205 incidentally discovered cases. Women represented 67.3% of the subjects included in the study and

206 the female predominance was most pronounced in MACS-2 (73.6%) and CS (86.2%) (**Table 1**).

207 The median age at the time of adrenal tumor diagnosis was 60 years (interquartile range 52-67

208 years). Subjects with MACS were older than those with NFAT (**Fig. 2A**). By contrast, CS was

209 diagnosed at a younger age (median 48 years, interquartile range 38-60 years) (**Table 1**). Subjects

210 with abnormal 1mg-DST results had larger adrenal tumors, with over half of those with tumors >2

211 cm failing to suppress serum cortisol during the 1mg-DST (**Fig. 2B**).

212 Plasma ACTH was negatively associated with 1mg-DST results (**Appendix Table 4**), which was

213 reflected in a progressive decrease in ACTH from MACS-1 over MACS-2 to CS (**Table 1, Fig.**

214 **2C**). Serum DHEAS had a similar trend, but the differences among groups were less pronounced

215 (**Appendix Table 4, Fig. 2D**).

216 Persons with MACS were almost twice as likely to present with bilateral tumors than persons with

217 NFAT (30.1% vs. 16.5%) (**Table 1**). Persons with bilateral tumors had abnormal 1mg-DST results

218 in 62.3% and presented with larger adrenal masses (the maximum diameter of the larger adrenal

219 mass was considered), lower plasma ACTH, and higher 24-hour UFC (**Appendix Table 5**).

220 **Cardiometabolic disease burden**

221 In comparison to NFAT, subjects with MACS-2 and CS showed higher prevalence of hypertension

222 (age-, sex-, and BMI-adjusted prevalence ratios [aPRs] 1.15 [95%CI 1.04-1.27] and 1.37 [95%CI

223 1.16-1.62], respectively) (**Table 2, Fig. 3A**) and more often required ≥3 anti-hypertensives,

224 increasing with the degree of cortisol excess (MACS-2 aPR 1.31 [95%CI 1.02-1.68] and CS aPR

225 2.22 [95%CI 1.62-3.05]) (**Table 2, Fig. 3B**).

226 The prevalence of type 2 diabetes was increased in subjects with CS (aPR 1.62 [95%CI 1.08-

227 2.42]). In a subgroup analysis of persons with type 2 diabetes, both MACS-2 and CS more often

228 required insulin treatment (aPR 1.89 [95%CI 1.01-3.52] and 3.06 [95%CI 1.60-5.85], respectively)

229 (**Table 2, Fig. 3B**).

230 The prevalence of dyslipidemia did not differ from NFAT in MACS and CS.

231 None of the available clinical or biochemical characteristics (such as tumor diameter, 1mg-DST

232 results considered as a continuous variable, plasma ACTH, serum DHEAS, and 24-hour UFC)

233 correlated in a clinically meaningful way with the presence of cardiometabolic disease in the

234 EURINE-ACT study participants (**Appendix Table 6**).

235 Patients with bilateral adrenal tumors more often required ≥3 anti-hypertensives (43.4% vs. 35.2%

236 in unilateral tumors; aPR 1.28 [95%CI 1.06-1.55]) and were more frequently diagnosed with

237 dysglycemia (58.3% vs. 49.7%; aPR 1.15 [95%CI 1.02-1.31]) (**Appendix Table 5**). When we

238 further stratified these observations according to the 1mg-DST results, only patients with bilateral

239 tumors and MACS had an increased cardiometabolic burden (**Appendix Table 5**).

240 **Urinary steroid excretion**

241 When compared to NFAT, persons with MACS-1, MACS-2, and CS showed a gradual decrease

242 in the 24-hour urinary excretion of androgen metabolites (androsterone, etiocholanolone,

243 dehydroepiandrosterone [DHEA]) and of pregnenetriol (5-PT), the metabolite of the immediate

244 DHEA precursor 17-hydroxypregnenolone, (**Table 3**). Conversely, we observed a progressive

245 increase in the 24-hour urinary excretion of cortisol and tetrahydro-11-deoxycortisol (THS), the

246 metabolite of the immediate cortisol precursor 11-deoxycortisol. In MACS-2 and CS, the excretion

247 of cortisone was also increased (**Table 3**).

248 **DISCUSSION**

249 In this cross-sectional study, we showed that persons with benign adrenal tumors diagnosed with

250 MACS-2 and adrenal CS had an increased prevalence and severity of hypertension as compared

251 to NFAT. Persons with adrenal CS were also more likely to have a diagnosis of type 2 diabetes

252 and persons with MACS-2 and CS who had type 2 diabetes more often required insulin therapy to

253 achieve adequate glycemic control. Our data demonstrate that persons with MACS-2 carry an

254 increased cardiometabolic burden similar to that observed in CS, even if they do not display typical

255 features of clinically overt cortisol excess. We also show progressive changes in steroid excretion

256 in all four adrenal tumor subgroups, with decreased androgen and increased glucocorticoid

257 precursor excretion already present in persons with NFAT and increased glucocorticoid excretion

258 in MACS-1.

259 These findings were generated utilizing the largest ever prospectively recruited group of persons

260 with benign adrenal tumors, participants of the ENSAT EURINE-ACT study (3). We classified

261 subjects into four subgroups, NFAT, MACS-1, MACS-2, and CS, based on 1mg-DST results and

262 clinical presentation, according to the criteria defined in the 2016 European Society of

263 Endocrinology/ENSAT guidelines on adrenal incidentalomas (6).

264 Increased cardiometabolic risk is a well-established feature of clinically overt CS, while the

265 evidence regarding a metabolically adverse impact of MACS has been limited by small study sizes

266 and heterogeneous definitions of diagnosis and clinical outcomes (8). However, a picture of

267 increased cardiometabolic disease burden and frailty in persons with MACS has emerged from

268 previous studies (8, 17-21). Our data demonstrate in a large prospective group that failure to

269 suppress serum cortisol in the 1mg-DST increased the prevalence of cardiometabolic disease in

270 persons with MACS-2 and CS. Though cardiometabolic disease burden was not increased in

271 MACS-1, urinary multi-steroid profiling by mass spectrometry demonstrated decreased androgen

272 excretion and increased excretion of cortisol. Our steroid data suggest that NFAT, MACS-1 and

273 MACS-2 represent a gradually progressive continuum, which is also supported by the fact that

274 approximately 9% of subjects with NFAT develop MACS over time (8). To explore this further,

275 we stratified the EURINE-ACT NFAT group at a more granular level according to their 1mg-DST

276 result, demonstrating an increased cardiometabolic burden with each 10 nmol/L increment in

277 serum cortisol in the 1-mg DST (**Appendix Fig. 2**). We speculate that a subgroup of subjects with

278 NFAT may have underlying autonomous cortisol secretion that is not detected when applying the

279 current diagnostic criteria for cortisol excess, namely the 1mg-DST.

280 In our study of 1305 persons with benign adrenal tumors, 45.3% fulfilled the diagnostic criteria

281 for MACS according to 1mg-DST results. The prevalence of MACS in our study is higher than

282   previously reported, though direct comparison is hampered because of the heterogeneous

283   approaches to the definition of MACS prior to the 2016 consensus (6), including different DST

284   protocols and cut-offs and combination of DST results with other parameters such as ACTH, 24-

285   hour urinary free cortisol excretion, and salivary cortisol (8). However, a retrospective study in

286   198 persons with adrenal incidentalomas diagnosed MACS in 34.8% of cases according to the

287   same diagnostic criteria we used in this study (7). A very recent study (26) reported increased

288   mortality in patients with adrenal incidentaloma who had a serum cortisol of 83 nmol/L or higher

289   in the 1-mg DST, which increased in persons with a post-dexamethasone cortisol of 138 nmol/L

290   or higher, i.e. MACS-2, adding further evidence to a continuum of gradually increasing

291   cardiometabolic burden.

292   Persons included in the study were predominantly women and more than half of those were over

293   the age of 60 at the time of adrenal tumor diagnosis; the demographics of our prospectively

294   recruited study participants resemble those of large retrospective studies on adrenal incidentalomas

295   (27-29). We also found that the proportion of women increased with the degree of cortisol excess,

296   corroborating previous observations that cortisol excess predominantly affects women (7, 30).

297   Previous smaller studies found that subjects with bilateral and larger tumors are more likely to be

298   diagnosed with MACS (31, 32). We found in our much larger study that individuals with MACS

299   and bilateral tumors were more frequently diagnosed with dysglycemia and prescribed ≥3 anti-

300   hypertensives. We did not include subjects with cortisol excess due to primary bilateral

301   macronodular adrenal hyperplasia in whom this diagnosis had been ascertained by typical imaging

302   findings, positive family history and/or documentation of gene mutations in germline DNA.

303   Primary bilateral macronodular adrenal hyperplasia is a very rare cause of hypercortisolism that

14

304 regularly presents with MACS. Thus, some further cases of undiagnosed primary bilateral

305 macronodular adrenal hyperplasia in our study cannot be ruled out (33).

306 Strengths of our study include the prospective recruitment, the large sample size, the standardized

307 classification of different degrees of cortisol excess, and the 24-hour urine multi-steroid profiling

308 carried out by a centralized tandem mass spectrometry assay. To our knowledge, this is the largest

309 prospective study to establish the extent of the cardiometabolic disease burden in persons with

310 benign adrenal tumors with and without cortisol excess.

311 Weaknesses of our study include its cross-sectional design, precluding the collection of

312 longitudinal data about cardiometabolic outcomes, and the absence of a comparator group of

313 persons who also underwent imaging under similar circumstance but without being diagnosed with

314 an adrenal tumor. Routine biochemical assessments were not standardized across participating

315 centers and not measured in a centralized fashion. However, while we acknowledge that results

316 for 24h UFC, plasma ACTH, and serum DHEAS should be interpreted with caution, inter-assay

317 variability of serum cortisol measurements is unlikely to affect the cut-off of 50 nmol/L used to

318 diagnose MACS (34). We could not include 283 (18%) of the overall 1588 eligible ENSAT

319 EURINE-ACT participants with benign adrenal tumors in this study as they had no recorded 1mg-

320 DST results at the time of adrenal tumor diagnosis. Therefore, a degree of selection bias is possible

321 and should be taken into account when interpreting the high prevalence of MACS in our study.

322 However, 213 of the 283 persons excluded due to missing 1-mg DST results were recruited by the

323 four German centers who initially did not test their participants with the 1-mg DST, which makes

324 a relevant impact of selection bias unlikely.

325 In conclusion, our study demonstrates that MACS-2 and CS are clinically highly relevant

326 metabolic risk conditions, which predominantly affect women and come with increased prevalence

327 of hypertension and type 2 diabetes, and present with a more severe clinical phenotype than

328 persons with NFAT. Affected individuals should receive a comprehensive cardiovascular risk

329 assessment at the time of adrenal tumor diagnosis, with particular attention to blood pressure and

330 glucose metabolism. Future studies are required to further dissect cardiometabolic risk in MACS-

331 1 and NFAT and to identify biomarkers suitable for prediction of metabolic risk and assessment

332 of risk-mitigating interventions.

Contributors

A.P. and W.A. designed the study, with contributions from I.B., V.C., A.S. and K.N. A.P. contributed to data collection, data analysis, data interpretation, and co-wrote the manuscript. A.S. and K.N. performed statistical analyses and co-wrote the manuscript. A.J.S. reviewed the statistical analyses and edited the manuscript. A.E.T., L.C.G, and C.J. carried out the steroid excretion analysis by mass spectrometry and edited the manuscript. I.B., V.C. S.T., K.L., M.M., D.A.D, I.D.P., G.R, L.V.M., T.D., M.B., M.W.O.R., T.B., C.Z., T.D., A.D., M.A., A.K., D.L., J.R.M., M.Q., G.A.U., M.C.D., F.B., A.T., M.F., M.I., M.T., D.K., W.F.Y. Jr, K.N.M., U.A., and D.A.V. contributed to data collection and edited the manuscript. W.A. contributed to data analysis and data interpretation, co-wrote the manuscript, and supervised all steps of the conduct of the study.

Declaration of interests

The authors do not declare a conflict of interest in relation to this work.

Reproducible Research Statement

Protocol: not available.

Computer Code: available upon request to be sent to the corresponding author.

Data: we have provided a detailed description of the statistical analysis undertaken. We may share de-identified, individual participant-level data that underlie the results reported in this article on receipt of a request detailing the study hypothesis and statistical analysis plan; all requests should be sent to the corresponding author.

17

Author academic degrees and mailing addresses

- Alessandro Prete, MD. Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

- Anuradhaa Subramanian, MSc. Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

- Irina Bancos, MD. Division of Endocrinology, Diabetes, Metabolism and Nutrition. Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

- Vasileios Chortis, MD PhD. Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

- Stylianos Tsagarakis, MD PhD. Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Ipsilantou 45-47, Athens, Greece.

- Katharina Lang, MD. Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

- Magdalena Macech, MD. Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Żwirki i Wigury 61, 02-091, Warsaw, Poland.

- Danae A. Delivanis, MD. Division of Endocrinology, Diabetes, Metabolism and Nutrition. Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

- Ivana D. Pupovac, MD. Department of Endocrinology, University Hospital Centre Zagreb, Kišpatićeva ul. 12, 10000, Zagreb, Croatia.

- Giuseppe Reimondo, MD. Division of Internal Medicine, University of Turin, San Luigi Hospital, Regione Gonzole, 10, 10043, Orbassano, Turin, Italy.

- Ljiljana V. Marina, MD PhD. Department for Obesity, Reproductive and Metabolic Disorders, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, dr Subotića starijeg 8, Belgrade, Serbia.

- Timo Deutschbein, MD. Medicover Oldenburg MVZ, Elisenstraße 12, 26122, Oldenburg, Germany.

397 • Maria Balomenaki, MD. Department of Endocrinology, Diabetes and Metabolism, Evangelismos
398 Hospital, Ipsilantou 45-47, Athens, Greece.

399 • Michael W. O'Reilly, MD PhD. Department of Medicine, Royal College of Surgeons in Ireland,
400 University of Medicine and Health Sciences, 123, 2 St Stephen's Green, Dublin, D02 YN77, Republic
401 of Ireland.

402 • Lorna C. Gilligan, MD PhD, Institute of Metabolism and Systems Research, College of Medical and
403 Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

404 • Carl Jenkinson, PhD, Institute of Metabolism and Systems Research, College of Medical and Dental
405 Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

406 • Tomasz Bednarczuk, MD PhD. Department of Internal Medicine and Endocrinology, Medical
407 University of Warsaw, Żwirki i Wigury 61, 02-091, Warsaw, Poland.

408 • Catherine D. Zhang, MD. Division of Endocrinology, Diabetes, Metabolism and Nutrition. Mayo
409 Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

410 • Tina Dusek, MD PhD. Department of Endocrinology, University Hospital Centre Zagreb, Kišpatićeva
411 ul. 12, 10000, Zagreb, Croatia.

412 • Aristidis Diamantopoulos, MD. Department of Endocrinology, Diabetes and Metabolism,
413 Evangelismos Hospital, Ipsilantou 45-47, Athens, Greece.

414 • Miriam Asia, MSc. Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals
415 Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, B15 2TH, United Kingdom.

416 • Agnieszka Kondracka, MD PhD. Department of Internal Medicine and Endocrinology, Medical
417 University of Warsaw, Żwirki i Wigury 61, 02-091, Warsaw, Poland.

418 • Dingfeng Li, MD. Division of Endocrinology, Diabetes, Metabolism and Nutrition. Mayo Clinic, 200
419 First Street SW, Rochester, MN, 55905, USA.

420 • Jimmy R. Masjkur, MD. Department of Medicine III and Institute of Clinical Chemistry and Laboratory
421 Medicine, Technische Universität Dresden, 01069, Dresden, Germany.

422 • Marcus Quinkler, MD. Endocrinology in Charlottenburg, Stuttgarter Platz 1, 10627, Berlin, Germany.

423 • Grethe Å. Ueland, MD PhD. Department of Endocrinology, Haukeland University Hospital, 5021,
424 Bergen, Norway

425 • M. Conall Dennedy, MD PhD. Department of Endocrinology, University Hospital Galway, Newcastle
426 Rd, Galway, H91 YR71, Republic of Ireland.

427 • Felix Beuschlein, MD. Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitäts-
428 Spital Zürich (USZ) und Universität Zürich (UZH), Rämistrasse 100, 8091 Zurich, Switzerland.

429 • Antoine Tabarin, MD PhD. Service d'Endocrinologie, Centre Hospitalier Universitaire, Hopital du Haut
430 Leveque, Avenue Magellan 33600, Pessac, France.

431 • Martin Fassnacht, MD. Department of Internal Medicine I, Division of Endocrinology and Diabetes,
432 University Hospital, University of Würzburg, osef-Schneider-Straße 2, 97080 Würzburg, Germany.

433 • Miomira Ivovic, MD PhD. Department for Obesity, Reproductive and Metabolic Disorders, Clinic for
434 Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia, Faculty of
435 Medicine, University of Belgrade, dr Subotića starijeg 8, Belgrade, Serbia.

436 • Massimo Terzolo, MD. Division of Internal Medicine, University of Turin, San Luigi Hospital, Regione
437 Gonzole, 10, 10043, Orbassano, Turin, Italy.

438 • Darko Kastelan, MD PhD. Department of Endocrinology, University Hospital Centre Zagreb,
439 Kišpatićeva ul. 12, 10000, Zagreb, Croatia.

440 • William F. Young Jr, MD. Division of Endocrinology, Diabetes, Metabolism and Nutrition. Mayo
441 Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

442 • Konstantinos N. Manolopoulos, MD PhD. Institute of Metabolism and Systems Research, College of
443 Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

444 • Urszula Ambroziak, MD PhD. Department of Internal Medicine and Endocrinology, Medical
445 University of Warsaw, Żwirki i Wigury 61, 02-091, Warsaw, Poland.

446 • Dimitra A. Vassiliadi, MD. Department of Endocrinology, Diabetes and Metabolism, Evangelismos

447 Hospital, Ipsilantou 45-47, Athens, Greece.

448 • Angela E. Taylor, PhD. Institute of Metabolism and Systems Research, College of Medical and Dental

449 Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

450 • Alice J. Sitch, PhD. Institute of Applied Health Research, College of Medical and Dental Sciences,

451 University of Birmingham, Birmingham, B15 2TT, United Kingdom.

452 • Krishnarajah Nirantharakumar, MD. Institute of Applied Health Research, College of Medical and

453 Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

454 • Wiebke Arlt, MD DSc. Institute of Metabolism and Systems Research, College of Medical and Dental

455 Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

456 **Figure legends**

457 **Figure 1: Flow-chart of patient inclusion.**

458 **Figure 2: Endocrine assessment results.**

459 Distribution of serum cortisol (median, range) after the 1mg-overnight dexamethasone suppression

460 test (1mg-DST) according to age (A) and maximum tumor diameter (B) in subjects without clinical

461 signs of Cushing's syndrome. Plasma ACTH (C) and serum DHEAS (D) measured in these

462 subjects are shown as boxplots, with boxes representing median and interquartile range, and

463 whiskers representing 5th to 95th centile. The dotted lines in panels A and B represent the cortisol

464 cut-offs that separate non-functioning adrenal tumors (NFAT) from possible mild autonomous

465 cortisol secretion (MACS-1) and definitive mild autonomous cortisol secretion (MACS-2).

466 **Figure 3: Impact of different degrees of cortisol excess on the cardiometabolic risk.**

467 Poisson regression models with robust variance exploring the cardiometabolic risk of patients with

468 mild autonomous cortisol secretion (MACS) and adrenal Cushing's syndrome (CS) in comparison

469 to patients with non-functioning adrenal tumors (NFAT). Age-, sex-, and BMI-adjusted prevalence

470 ratios and 95% confidence intervals are reported. Panel A: adjusted prevalence ratios for

471 hypertension, dysglycemia, type 2 diabetes, and dyslipidemia. Panel B: adjusted prevalence ratios

472 for treatment with ≥3 anti-hypertensives (in subjects with hypertension) and insulin (in subjects

473 with type 2 diabetes).

References

474

475 1. Song JH, Chaudhry FS, Mayo-Smith WW**.** The incidental adrenal mass on CT: prevalence
476   of adrenal disease in 1,049 consecutive adrenal masses in patients with no known
477   malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8.

478 2. Reimondo G, Castellano E, Grosso M, et al. Adrenal Incidentalomas are Tied to Increased
479   Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab.
480   2020;105(4):e973–e81.

481 3. Bancos I, Taylor AE, Chortis V, et al. Urine steroid metabolomics for the differential
482   diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test
483   validation study. Lancet Diabetes Endocrinol. 2020;8(9):773-81.

484 4. Nieman LK**.** Cushing's syndrome: update on signs, symptoms and biochemical screening.
485   Eur J Endocrinol. 2015;173(4):M33-8.

486 5. Mancini T, Kola B, Mantero F, et al. High cardiovascular risk in patients with Cushing's
487   syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf).
488   2004;61(6):768-77.

489 6. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European
490   Society of Endocrinology Clinical Practice Guideline in collaboration with the European
491   Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34.

492 7. Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients
493   with adrenal incidentalomas that are either non-secreting or associated with intermediate
494   phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet
495   Diabetes Endocrinol. 2014;2(5):396-405.

496 8. Elhassan YS, Alahdab F, Prete A, et al. Natural History of Adrenal Incidentalomas With
497   and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis.
498   Ann Intern Med. 2019;171(2):107-16.

499 9. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an
500   Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-
501   40.

502 10. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of
503   patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin
504   Endocrinol Metab. 2008;93(9):3266-81.

505 11. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case
506   Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J
507   Clin Endocrinol Metab. 2016;101(5):1889-916.

508 12. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and
509   treatment. A scientific statement from the American Heart Association Professional
510   Education Committee of the Council for High Blood Pressure Research. Hypertension.
511   2008;51(6):1403-19.

512 13. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical
513   Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33.

514 14. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary
515   Prevention of Cardiovascular Disease: A Report of the American College of
516   Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
517   Circulation. 2019;140(11):e596-e646.

518 15. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an
519   empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res
520   Methodol. 2003;3:21.

521 16. Cole TJ. Sympercents: symmetric percentage differences on the 100 log(e) scale simplify
522   the presentation of log transformed data. Stat Med. 2000;19(22):3109-25.

523 17. Di Dalmazi G, Vicennati V, Pizzi C, et al. Prevalence and Incidence of Atrial Fibrillation
524   in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study. J Clin Endocrinol
525   Metab. 2020;105(8):e2770-e7.

526 18. Singh S, Atkinson EJ, Achenbach SJ, et al. Frailty in Patients With Mild Autonomous
527   Cortisol Secretion is Higher Than in Patients with Nonfunctioning Adrenal Tumors. J Clin
528   Endocrinol Metab. 2020;105(9):e3307-e15.

529 19. Chiodini I, Torlontano M, Scillitani A, et al. Association of subclinical hypercortisolism
530   with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J
531   Endocrinol. 2005;153(6):837-44.

532 20. Petramala L, Olmati F, Concistre A, et al. Cardiovascular and metabolic risk factors in
533   patients with subclinical Cushing. Endocrine. 2020;70(1):150-63.

534   21.   Oki K, Yamane K, Nakanishi S, et al. Influence of adrenal subclinical hypercortisolism on
535   hypertension in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes.
536   2012;120(4):244-7.

537   22.   Khan U. Nonfunctioning and Subclinical Cortisol Secreting Adrenal Incidentalomas and
538   their Association with Metabolic Syndrome: A Systematic Review. Indian J Endocrinol
539   Metab. 2019;23(3):332-46.

540   23.   Lopez D, Luque-Fernandez MA, Steele A, et al. "Nonfunctional" Adrenal Tumors and the
541   Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study. Ann Intern
542   Med. 2016;165(8):533-42.

543   24.   Arruda M, Mello Ribeiro Cavalari E, Pessoa de Paula M, et al. The presence of
544   nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and
545   severity, and is associated with cortisol levels after dexamethasone suppression test. J Hum
546   Hypertens. 2017;32(1):3-11.

547   25.   Kim JH, Kim MJ, Lee JH, et al. Nonfunctioning Adrenal Incidentalomas are not Clinically
548   Silent: A Longitudinal Cohort Study. Endocr Pract. 2020;26(12):1406-15.

549   26.   Kjellbom A, Lindgren O, Puvaneswaralingam S, et al. Association Between Mortality and
550   Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas : A Cohort Study.
551   Ann Intern Med. 2021;174(8):1041-9.

552   27.   Iniguez-Ariza NM, Kohlenberg JD, Delivanis DA, et al. Clinical, Biochemical, and
553   Radiological Characteristics of a Single-Center Retrospective Cohort of 705 Large Adrenal
554   Tumors. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):30-9.

555   28.   Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study
556   Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol
557   Metab. 2000;85(2):637-44.

558   29.   Kasperlik-Zaluska AA, Otto M, Cichocki A, et al. Incidentally discovered adrenal tumors:
559   a lesson from observation of 1,444 patients. Horm Metab Res. 2008;40(5):338-41.

560   30.   Invitti C, Pecori Giraldi F, de Martin M, et al. Diagnosis and management of Cushing's
561   syndrome: results of an Italian multicentre study. Study Group of the Italian Society of
562   Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin
563   Endocrinol Metab. 1999;84(2):440-8.

564   31.   Vassiliadi DA, Ntali G, Vicha E, et al. High prevalence of subclinical hypercortisolism in
565   patients with bilateral adrenal incidentalomas: a challenge to management. Clin Endocrinol
566   (Oxf). 2011;74(4):438-44.
567   32.   Olsen H, Nordenstrom E, Bergenfelz A, et al. Subclinical hypercortisolism and CT
568   appearance in adrenal incidentalomas: a multicenter study from Southern Sweden.
569   Endocrine. 2012;42(1):164-73.
570   33.   Bouys L, Chiodini I, Arlt W, et al. Update on primary bilateral macronodular adrenal
571   hyperplasia (PBMAH). Endocrine. 2021;71(3):595-603.
572   34.   Raverot V, Richet C, Morel Y, et al. Establishment of revised diagnostic cut-offs for
573   adrenal laboratory investigation using the new Roche Diagnostics Elecsys((R)) Cortisol II
574   assay. Ann Endocrinol (Paris). 2016;77(5):620-2.
575

Table 1: Demographics, radiological, and biochemical parameters of EURINE-ACT participants with benign adrenocortical adenomas who underwent assessment for cortisol excess.

Values are reported as median (interquartile range), unless otherwise stated. Abbreviations: 1mg-DST, 1mg-overnight dexamethasone suppression test; ACTH, adrenocorticotropic hormone; BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; UFC, urinary free cortisol. NFAT, non-functioning adrenal tumors; MACS, mild autonomous cortisol secretion; CS, Cushing's syndrome.

	Overall cohort (n=1305)	NFAT (n=649)	MACS-1 (n=451)	MACS-2 (n=140)	Adrenal CS (n=65)
Women, n (%)	878 (67.3)	416 (64.1)	303 (67.2)	103 (73.6)	56 (86.2)
Age (years)	60 (52-67)	58 (51-65)	64 (56-71)	63 (54-69)	48 (38-60)
BMI (kg/m^2)	29.0 (25.4-33.4)	29.4 (25.8-33.9)	28.8 (25.1-33.1)	28.6 (24.0-32.9)	28.7 (25.2-31.7)
- Lean (BMI <25), n (%)	292 (22.9)	129 (20.6)	106 (23.8)	42 (30.0)	15 (23.4)
- Overweight (BMI 25-30), n (%)	429 (33.6)	202 (32.2)	160 (35.9)	41 (29.3)	26 (40.6)
- Obesity (BMI ≥30), n (%)	556 (43.5)	296 (47.2)	180 (40.4)	57 (40.7)	23 (35.9)
Maximum tumor diameter (mm)[*]	26 (19-36)	22 (16-30)	30 (23-38)	32 (24-44)	30 (26-38)
Tumor location:					
- Left adrenal, n (%)	616 (47.2)	323 (49.8)	196 (43.5)	63 (45.0)	34 (52.3)
- Right adrenal, n (%)	391 (30)	219 (33.7)	119 (26.4)	35 (25.0)	18 (27.7)
- Bilateral, n (%)	298 (22.8)	107 (16.5)	136 (30.2)	42 (30.0)	13 (20.0)
Serum cortisol in the 1mg-DST (nmol/L)	51 (33-92)	33 (27-41)	72 (60-93)	200 (165-283)	435 (271-574)
Plasma ACTH (pmol/L)	2.38 (1.34-3.96)	3.00 (1.89-4.89)	2.20 (1.30-3.43)	1.43 (0.55-2.60)	0.66 (0.55-1.43)
Serum DHEAS (µmol/L)	1.40 (0.70-2.70)	1.90 (1.00-3.40)	1.14 (0.65-2.19)	0.83 (0.40-1.85)	0.54 (0.23-1.58)
24-hour UFC (nmol/24h)	132 (66-226)	127 (66-207)	141 (69-229)	130 (47-207)	472 (149-1319)

[*] For bilateral tumors, the maximum diameter of the larger adrenal mass was considered.

Table 2: Cardiometabolic disease burden in benign adrenocortical tumors with different degrees of cortisol excess.
Series of Poisson regression model with robust variance was employed to investigate the cardiometabolic burden of 1305 persons from the EURINE-ACT study. Unadjusted and adjusted prevalence ratios are reported; adjusted models included age, sex and BMI as covariates. Missing outcome data were replaced using multiple imputation using chained equations with age, sex, and BMI as covariates. Imputations for treatment with ≥3 anti-hypertensives, type 2 diabetes and insulin treatment were conditional to patients with hypertension, dysglycemia and type 2 diabetes, respectively. Abbreviations: NFAT, non-functioning adrenal tumors; MACS, mild autonomous cortisol secretion; CS, Cushing's syndrome.

	NFAT (n=649)	MACS-1 (n=451)	MACS-2 (n=140)	Adrenal CS (n=65)
Hypertension, n (%)	416 (64.1)	339 (75.2)	107 (76.4)	47 (72.3)
Prevalence ratios (95% CI)		1.17 (1.08-1.27)	1.19 (1.07-1.33)	1.13 (0.96-1.33)
Adjusted prevalence ratios (95% CI)		1.07 (0.99-1.16)	1.15 (1.04-1.27)	1.37 (1.16-1.62)
Treatment with ≥3 anti-hypertensives, n (%)[*]	142 (34.3)	132 (39.1)	46 (43.0)	27 (57.4)
Prevalence ratios (95% CI)		1.14 (0.94-1.38)	1.25 (0.97-1.63)	1.68 (1.26-2.23)
Adjusted prevalence ratios (95% CI)		1.12 (0.92-1.37)	1.31 (1.02-1.68)	2.22 (1.62-3.05)
Dysglycemia, n (%)[†]	321 (49.5)	243 (53.9)	77 (55.0)	32.4 (49.8)
Prevalence ratios (95% CI)		1.09 (0.97-1.23)	1.11 (0.91-1.35)	1.01 (0.75-1.34)
Adjusted prevalence ratios (95% CI)		1.00 (0.89-1.13)	1.07 (0.89-1.29)	1.23 (0.92-1.65)
Type 2 diabetes, n (%)	171 (26.4)	145 (32.2)	47 (33.7)	20 (31.5)
Prevalence ratios (95% CI)		1.22 (1.00-1.49)	1.27 (0.95-1.72)	1.19 (0.80-1.78)
Adjusted prevalence ratios (95% CI)		1.10 (0.91-1.33)	1.23 (0.92-1.64)	1.62 (1.08-2.42)
Insulin treatment, n (%)[‡]	29 (16.9)	37 (25.8)	15 (32.6)	8 (41.0)
Prevalence ratios (95% CI)		1.53 (0.92-2.56)	1.94 (1.05-3.59)	2.44 (1.25-4.76)
Adjusted prevalence ratios (95% CI)		1.45 (0.83-2.52)	1.89 (1.01-3.52)	3.06 (1.60-5.85)
Dyslipidemia, n (%)	187 (28.8)	161 (35.7)	50 (35.9)	10 (15.7)
Prevalence ratios (95% CI)		1.24 (1.04-1.47)	1.24 (0.96-1.60)	0.54 (0.30-0.97)
Adjusted prevalence ratios (95% CI)		1.08 (0.91-1.29)	1.18 (0.91-1.52)	0.76 (0.43-1.32)

[*] Considering only subjects with a diagnosis of hypertension (n=909).
[†] Dysglycemia includes subjects with pre-diabetes and type 2 diabetes.
[‡] Considering only subjects with a diagnosis of type 2 diabetes (n=383).

Table 3: 24-hour steroid metabolite excretion in persons with benign adrenocortical tumors and different degrees of cortisol excess. Steroid metabolites measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) of 24-h urine collected by persons with non-functioning adrenal tumors (NFAT), mild autonomous cortisol secretion (MACS-1 and MACS-2 listed separately), and adrenal Cushing's syndrome (CS). Values are reported as median (interquartile range) (μg/24h). The urinary excretion of each steroid metabolite in persons with MACS-1, MACS-2, and adrenal CS was compared to those with NFAT using a linear regression model with the log-transformed steroid metabolite as the outcome (adjusted for age, sex and BMI). Associations between the log-transformed outcome and the variable of interest are reported as sympercents.

		NFAT (n=649)	MACS-1 (n=451)	MACS-2 (n=140)	Adrenal CS (n=65)
An	median (IQR) 24-h excretion (μg/24h)	577 (258-1034)	290 (127-642)	191 (97-474)	167 (61-314)
	% change compared to NFAT (95% CI)		-38 (-51, -25)	-69 (-88, -50)	-115 (-142, -88)
Etio	median (IQR) 24-h excretion (μg/24h)	540 (264-1073)	364 (167-747)	329 (144-689)	331 (221-725)
	% change compared to NFAT (95% CI)		-26 (-38, -13)	-45 (-63, -26)	-39 (-65, -13)
DHEA	median (IQR) 24-h excretion (μg/24h)	26 (22-54)	22 (22-30)	22 (22-24)	22 (22-22)
	% change compared to NFAT (95% CI)		-17 (-27, -8)	-34 (-49, -20)	-56 (-76, -36)
5-PT	median (IQR) 24-h excretion (μg/24h)	92 (49-177)	63 (43-126)	56 (43-101)	71 (43-115)
	% change compared to NFAT (95% CI)		-16 (-25, -7)	-30 (-43, -16)	-28 (-47, -10)
5-PD	median (IQR) 24-h excretion (μg/24h)	81 (55-144)	64 (55-106)	56 (55-105)	89 (55-158)
	% change compared to NFAT (95% CI)		-9 (-17, -1)	-18 (-30, -7)	7 (-9, 24)
PD	median (IQR) 24-h excretion (μg/24h)	328 (190-597)	281 (157-479)	254 (149-503)	536 (206-813)
	% change compared to NFAT (95% CI)		-8 (-19, 3)	-17 (-33, -0.3)	16 (-7, 39)
PT	median (IQR) 24-h excretion (μg/24h)	333 (179-567)	257 (143-465)	210 (118-452)	222 (145-368)
	% change compared to NFAT (95% CI)		-8 (-17, 1)	-19 (-32, -6)	-26 (-45, -7)
17HP	median (IQR) 24-h excretion (μg/24h)	69 (39-135)	63 (37-127)	51 (32-108)	74 (45-116)
	% change compared to NFAT (95% CI)		6 (-4, 17)	-8 (-24, 7)	-1 (-23, 21)
THS	median (IQR) 24-h excretion (μg/24h)	141 (87-222)	142 (91-239)	177 (90-271)	317 (181-500)
	% change compared to NFAT (95% CI)		9 (0.4, 17)	20 (8, 32)	84 (67, 102)
Cortisol	median (IQR) 24-h excretion (μg/24h)	45 (28-65)	54 (32-82)	57 (33-92)	151 (76-344)
	% change compared to NFAT (95% CI)		23 (15, 32)	33 (21, 46)	131 (113, 148)

THF	median (IQR) 24-h excretion (µg/24h)	1362 (914-2011)	1460 (888-2165)	1563 (998-2293)	3163 (1466-6425)
	% change compared to NFAT (95% CI)		10 (-1, 22)	14 (-3, 30)	92 (69, 116)
5α-THF	median (IQR) 24-h excretion (µg/24h)	568 (287-986)	543 (267-947)	506 (206-823)	642 (315-1088)
	% change compared to NFAT (95% CI)		5 (-6, 15)	-5 (-21, 11)	30 (7, 52)
11β-OH-Et	median (IQR) 24-h excretion (µg/24h)	305 (120-541)	335 (135-613)	413 (156-769)	602 (182-1310)
	% change compared to NFAT (95% CI)		8 (-3, 19)	23 (7, 39)	60 (37, 83)
Cortisone	median (IQR) 24-h excretion (µg/24h)	73 (47-105)	76 (47-108)	82 (49-115)	141 (95-317)
	% change compared to NFAT (95% CI)		6 (-2, 14)	16 (4, 27)	84 (67, 100)
THE	median (IQR) 24-h excretion (µg/24h)	2223 (1457-3409)	2181 (1334-3329)	2323 (1296-3170)	3812 (1939-5865)
	% change compared to NFAT (95% CI)		3 (-6, 12)	0 (-13, 13)	47 (28, 66)
β-cortolone	median (IQR) 24-h excretion (µg/24h)	634 (401-964)	624 (389-989)	658 (341-937)	998 (622-1632)
	% change compared to NFAT (95% CI)		5%(-4, 13)	0 (-13, 13)	54 (35, 73)